Logo
x

Search

Subscribe Now

Rapt Therapeutics

Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

  • April 10, 2024
The US FDA Places Clinical Hold on the Trials Assessing RAPT Therapeutics’ Zelnecirnon

The US FDA Places Clinical Hold on the Trials Assessing RAPT Therapeutics’ Zelnecirnon

  • February 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.